REBECCA LEBAS: Open Payments
NPI 1508450230 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,331 in 39 payments from 11 companies in 2025. Trend: 2023 $1,481 · 2024 $1,182 · 2025 $1,331
Food & beverage: $1,331
| Company | Payments | Amount |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 14 | $550 |
| Novo Nordisk Inc | 7 | $210 |
| ABIOMED | 4 | $186 |
| Bard Peripheral Vascular, Inc. | 1 | $152 |
| Novartis Pharmaceuticals Corporation | 3 | $69 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 4 | $61 |
| Amgen Inc. | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: Assure WCD, Venclose Maven Catheter, Ozempic, LEQVIO, Wegovy, LifeVest, REPATHA, JARDIANCE.
Industry payments across LA — which companies pay providers there.
